Existing stent retrievers designed for neurovascular diseases such as ischemic and hemorrhagic stroke lack any adjustability ­ they open passively and are pulled from the brain fully expanded. Now, an adjustable clot retriever designed to remove thrombus from delicate brain blood vessels during an ischemic stroke can provide new safety levels for higher-risk thrombectomies.

Rapid Medical’s (Yokneam, Israel) TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices. The unique adjustability of the TIGERTRIEVER portfolio comes from complex three-dimensional braiding borrowed from recent advances in aerospace engineering.

TIGERTRIEVER is precisely controlled to capture the thrombus and remove the tension from the vasculature before removal. Adjustability also gives TIGERTRIEVER 13 the lowest profile of any stent retriever - 24% smaller than 3 mm devices, providing easier navigation in challenging anatomies. The ability to tailor each procedure can provide new safety levels for higher-risk thrombectomies. Rapid Medical has received FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions.

“Thousands of procedures have already been performed with TIGERTRIEVER 13 worldwide,” said James Romero, President, Americas, of Rapid Medical. “Now U.S. physicians finally have access to TIGERTRIEVER 13’s unique capabilities to further benefit patients suffering from ischemic stroke.”

“The neurovascular field has been waiting for a thrombectomy device dedicated to small vessels,” stated Dr. David Fiorella of Stony Brook University Medical Center. “Medical therapy is currently suboptimal for these patients, so there can be a huge benefit for devices that emergently restore blood flow while minimizing the potential for harm.” 

http://www.gzjiayumed.com/en/index.asp